Oury Chetboun, Founder and CEO at Seekyo Therapeutics, shared a post on LinkedIn:
“Built for the patients conventional ADCs leave behind.
While traditional ADCs rely on antigen expression, Seekyo Therapeutics’ SKY01 / Tumor Activated Therapy™ takes a different approach:
- No target expression required
- No escape through tumor heterogeneity
- No resistance induced
Instead, β-glucuronidase activity within the tumor microenvironment triggers payload activation directly at the tumor site.
- Antigen-independent
- Designed to overcome tumor heterogeneity
- Potentially applicable to cancers beyond the reach of conventional ADCs
Expanding the therapeutic opportunity where ADCs face their greatest limitations.”
Other articles featuring Oury Chetboun on OncoDaily.